Showing results (91-100 of 96) with videos related to
Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of SCH 900188: A Potent Hepatitis C Virus NS5B Polymerase Inhibitor Prodrug As a Development CandidateKevin X Chen, Srikanth Venkatraman, Gopinadhan N Anilkumar, et al.Journal of Medicinal Chemistry|January 18, 2012
A novel class of highly potent irreversible hepatitis C virus NS5B polymerase inhibitorsKevin X Chen, Charles A Lesburg, Bancha Vibulbhan, et al.Journal of Medicinal Chemistry|December 14, 2011
Structure-activity relationship (SAR) development and discovery of potent indole-based inhibitors of the hepatitis C virus (HCV) NS5B polymeraseKevin X Chen, Bancha Vibulbhan, Weiying Yang, et al.Journal of Medicinal Chemistry|April 28, 2006
Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replicationStéphane L Bogen, Ashok Arasappan, Frank Bennett, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease InhibitorAshok Arasappan, Frank Bennett, Stephane L Bogen, et al.Journal of Medicinal Chemistry|September 29, 2006
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infectionSrikanth Venkatraman, Stéphane L Bogen, Ashok Arasappan, et al.Pageof 10